Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CD | O00329 | 19/20 | 0.49 |
| ▸ | PIK3R1 | P27986 | 14/20 | 0.49 |
| ▸ | PIK3CG | P48736 | 9/20 | 0.49 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.49 |
| ▸ | PIK3CB | P42338 | 7/20 | 0.49 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.49 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.49 |
| ▸ | HTR2A | P28223 | 1/20 | 0.49 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Bosmolisib SCHEMBL29447648 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| Bosmolisib SCHEMBL20067908 | 1.00 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL25108192 | 0.93 | PIK3CD (0.49) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL25107462 | 0.92 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL25107215 | 0.92 | PIK3CD (0.44) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL25107607 | 0.91 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL22227555 | 0.91 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL20061377 | 0.91 | PIK3CD (0.48) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL29517501 | 0.91 | PIK3CD (0.47) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB | |
| SCHEMBL25107316 | 0.91 | PIK3CD (0.44) | PIK3CDPIK3R1PIK3CGPIK3CAPIK3CB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3312175-B1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2020-07-22 | — | — | EP | claimed |
| WO-2019139388-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PI3 KINASE INHIBITOR AND IMMUNE CHECKPOINT INHIBITOR FOR PREVENTING OR TREATING CANCER | 보령제약 주식회사 | 2019-07-18 | — | — | WO | claimed |
| WO-2019139399-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PI3 KINASE INHIBITOR AND CYTOTOXIC ANTI-CANCER AGENT FOR PREVENTING OR TREATING CANCER | 보령제약 주식회사 | 2019-07-18 | — | — | WO | claimed |
| US-12600718-B2 | Method for preparing compound as PI3K inhibitor and intermediate compound for preparing same | BORYUNG CORPORATION (KR) | 2026-04-14 | — | — | US | disclosed |
| EP-4174067-B1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | BORYUNG CORP (KR) | 2025-11-05 | — | — | EP | disclosed |
| US-20230295158-A1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | BORYUNG CORPORATION (KP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295158-A1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | BORYUNG CORPORATION (KP) | 2023-09-21 | — | — | US | disclosed |
| US-20230295158-A1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | BORYUNG CORPORATION (KP) | 2023-09-21 | — | — | US | disclosed |
| WO-2023080674-A1 | PHARMACEUTICAL COMPOSITION COMPRISING PI3K AND DNA-PK DUAL INHIBITOR FOR PREVENTING OR TREATING PERIPHERAL T CELL LYMPHOMA | 주식회사 보령 | 2023-05-11 | — | — | WO | disclosed |
| EP-4174067-A1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | Boryung Corporation (KR) | 2023-05-03 | — | — | EP | disclosed |
| US-20230072683-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-09 | — | — | US | disclosed |
| US-20230072683-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | BORYUNG PHARMACEUTICAL CO., LTD. (KR) | 2023-03-09 | — | — | US | disclosed |
| US-20220204502-A1 | CRYSTAL POLYMORPHISM OF PI3K INHIBITOR AND METHOD FOR PREPARING SAME | BORYUNG PHARMACEUTICAL CO., LTD (KR) | 2022-06-30 | — | — | US | disclosed |
| EP-3974427-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | Boryung Pharmaceutical Co., Ltd. (KR) | 2022-03-30 | — | — | EP | disclosed |
| WO-2020225783-A1 | CRYSTAL POLYMORPHISM OF PI3K INHIBITOR AND METHOD FOR PREPARING SAME | 보령제약 주식회사 | 2020-11-12 | — | — | WO | disclosed |
| WO-2020225782-A1 | AMORPHOUS PI3K INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 보령제약 주식회사 | 2020-11-12 | — | — | WO | disclosed |
| EP-3312175-B1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2020-07-22 | — | — | EP | disclosed |
| EP-3312175-B1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RES INST CHEMICAL TECH (KR) | 2020-07-22 | — | — | EP | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | KOREA RESEARCH INSTITUTE OF CHEMICAL TECHNOLOGY (KR) | 2018-04-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230295158-A1 | METHOD FOR PREPARING COMPOUND AS PI3K INHIBITOR AND INTERMEDIATE COMPOUND FOR PREPARING SAME | PIK3CA, PIK3CD, PIK3C2B | PIK3CD 2/4885PIK3R1 10/4885PIK3CG 4/4885 |
| US-20180105527-A1 | HETEROARYL DERIVATIVE OR PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, PREPARATION METHOD THEREFOR, AND PHARMACEUTICAL COMPOSTION FOR PREVENTING OR TREATING DISEASES ASSOCIATED WITH PI3 KINASES, CONTAINING SAME AS ACTIVE INGREDIENT | WEE2, WEE1, ITK | PIK3CD 14/4885PIK3R1 9/4885PIK3CG 19/4885 |
| US-20220204502-A1 | CRYSTAL POLYMORPHISM OF PI3K INHIBITOR AND METHOD FOR PREPARING SAME | PIK3C2A, PIK3CA, PIK3C2B | PIK3CD 6/4885PIK3R1 14/4885PIK3CG 18/4885 |
| US-12600718-B2 | Method for preparing compound as PI3K inhibitor and intermediate compound for preparing same | PIK3CA, MTOR, PIK3CD | PIK3CD 3/4885PIK3R1 28/4885PIK3CG 16/4885 |
| US-20230072683-A1 | PYRIDO-PYRIMIDIN DERIVATIVES AND PHARMACEUTICAL COMPOSITION, FOR USE IN PREVENTING OR TREATING PI3 KINASE RELATED DISEASES, COMPRISING SAME AS ACTIVE INGREDIENT | PIK3CA, PDXK, PIK3CD | PIK3CD 3/4885PIK3R1 27/4885PIK3CG 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.